New biomarker data provide additional evidence of the preliminary activity of ABBV-969, an investigational antibody-drug conjugate (ADC) designed to target both PSMA and STEAP1 in metastatic castration-resistant prostate cancer (mCRPC). The findings come from the ongoing Phase 1 study, involving 49 heavily pretreated patients who had received a median of five previous treatment lines. Most […]
Prostate cancer that develops neuroendocrine features is commonly associated with loss of androgen-receptor dependence and reduced PSMA expression, potentially making PSMA-targeted treatments less useful. A new dual-tracer imaging study suggests that the reality may be considerably more complicated. Researchers retrospectively examined eight men with metastatic castration-resistant prostate cancer who were suspected of developing treatment-emergent neuroendocrine […]
A new antibody-drug conjugate has received clearance to enter clinical trials in China with a double strategy for prostate cancer: instead of targeting PSMA or STEAP1, ICP-B381 targets both. The experimental bispecific ADC combines a humanised antibody recognising PSMA and STEAP1 with a proprietary cytotoxic payload connected through an irreversible linker. Both proteins are strongly […]
Neuroendocrine prostate cancer (NEPC) is a highly aggressive, treatment-resistant form of prostate cancer that emerges after androgen-deprivation therapies fail, leaving few effective options. Memorial Sloan Kettering Cancer Center is now running a Phase I trial testing a radiolabeled antibody called 177Lu-DTPA-SC16.56 in patients with progressive, chemotherapy-relapsed neuroendocrine prostate and lung cancers. DLL3 is the reason […]
MVB-101 (aka CBP-1018) is a new clinical-stage drug conjugate for prostate cancer simultaneously targets PSMA and folate receptor alpha (FRα) to overcome tumor heterogeneity. The drug is a bivalent peptide-like drug conjugate roughly one-fiftieth the size of a traditional antibody drug conjugate, designed to diffuse more rapidly into solid tumors. It delivers monomethyl auristatin E […]
ABBV-969 is a dual-target antibody-drug conjugate targeting PSMA and STEAP1, data about its radiographic progression-free survival data have just been released, confirming a median rPFS of approximately 15 months in heavily pretreated metastatic castration-resistant prostate cancer. The study demonstrates a signal far exceeding the 4- to 5-month rPFS historically seen with cabazitaxel in the same […]
ABBV-969, a first-in-class dual-targeting antibody-drug conjugate (ADC), is emerging as a promising new therapeutic candidate for patients with metastatic castration-resistant prostate cancer (mCRPC), particularly in the late-line setting where treatment options are limited and outcomes remain poor. Designed to simultaneously target prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), both highly […]
For prostate cancer patients with low expression of PSMA or with neuroendocrine prostate cancer or NEPC (a population growing in size precisely because better treatments are forcing tumors to adapt), a new preclinical study offers a credible precision-targeted strategy: a radiotheranostic pair built on the CEACAM5 surface antigen that produced complete tumor responses in every […]
QLS2401 is a trispecific T‑cell engager designed for metastatic castration‑resistant prostate cancer (mCRPC). It binds three targets at once: PSMA and STEAP1 on tumor cells, plus CD3 on T cells. This design allows it to physically connect a patient’s T cells to prostate‑cancer cells, triggering T‑cell activation and killing of the tumor. Both PSMA and […]
We have already talked about it here, GenSci143, is a novel bispecific antibody-drug conjugate targeting B7-H3 and PSMA, and a phase 1 trial is set to begin first-in-human clinical trials soon (est. date December 20) in participants with advanced solid tumors, including metastatic castration-resistant prostate cancer. Recent regulatory approvals were granted by the U.S. FDA […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy